A phase II trial of gallium nitrate (NSC # 15200) in advanced or recurrent squamous cell carcinoma of the cervix : a gynecologic oncology group study

Twenty-four evaluable patients with advanced, persistent or recurrent squamous cell carcinoma of the cervix were treated with 750 mg/m2 of gallium nitrate (NSC #15200) every three weeks. No patient had prior cytotoxic chemotherapy. Two patients had a partial response (8.3%), ten patients had stable...

Full description

Saved in:
Bibliographic Details
Published in:Investigational new drugs 1991-02, Vol.9 (1), p.109-111
Main Authors: MALFETANO, J. H, BLESSING, J. A, HOMESLEY, H. D, HANJANI, P
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic agents
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Carcinoma, Squamous Cell - drug therapy
Chemotherapy
Drug Evaluation
Female
Gallium - adverse effects
Gallium - therapeutic use
Humans
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Uterine Cervical Neoplasms - drug therapy
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Twenty-four evaluable patients with advanced, persistent or recurrent squamous cell carcinoma of the cervix were treated with 750 mg/m2 of gallium nitrate (NSC #15200) every three weeks. No patient had prior cytotoxic chemotherapy. Two patients had a partial response (8.3%), ten patients had stable disease (41.7%), and twelve (50%) had increasing disease. The 95% upper confidence bound for response is 24.0%. The major toxicities were nausea, vomiting and anemia. Gallium nitrate has minimal activity in patients with previously untreated squamous cell carcinoma of the cervix.
ISSN:0167-6997
1573-0646
DOI:10.1007/BF00194560